We report a rare case of ALK-rearranged lung squamous cell carcinoma with response to crizotinib therapy.
We highlight the challenges in the identification of this rare molecular subtype of lung cancer.
We point out the overlapping phenotypic criteria between ALK-rearranged squamous cell carcinomas and adenocarcinomas.